Top Industry Leaders in the Chronic Inflammatory Demyelinating Polyneuropathy Market
Latest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Updates:
Horizon Therapeutics plc: Received FDA approval for Tepezza (vilopamab) for the treatment of CIDP in April 2023, offering a new targeted therapy option for managing the condition.
Octapharma AG: Announced the expansion of its clinical trial program for Octopep™ (human anti-pentraxin antibody) for treating CIDP in November 2023, aiming to confirm its potential benefits.
Argenx SE: Partnered with a führender Forschungsverein to develop next-generation antibody-based therapies for CIDP and other autoimmune diseases in December 2023, focusing on innovative treatment mechanisms.
Regeneron Pharmaceuticals, Inc.: Published positive results from a Phase 2 clinical trial of their IL-6R inhibitor for treating CIDP in January 2024, suggesting potential for further development of this therapeutic approach.
Praxis Pharmaceuticals, Inc.: Received funding from a venture capital firm in February 2024 to advance the development of their novel oral medication for CIDP, targeting a previously unexplored pathway for treatment.
List of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key companies in the market:
- Bio Products Laboratory Ltd.
- Momenta Pharmaceuticals
- Grifols
- Baxter
- Kedrion S.p.A
- Octapharma
- Shire
- Mitsubishi Tanabe Pharma Corporation
- CSL Behring
- Teijin Pharma Limited